Related Experiment Video
Updated: Nov 18, 2025
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Preventing Brain Injury in the Preterm Infant-Current Controversies and Potential Therapies
Nathanael Yates1,2, Alistair J Gunn3, Laura Bennet3
1The Queensland Brain Institute, University of Queensland, St Lucia, QLD 4072, Australia.
Insights
Preterm birth poses risks for infant brain injury and cerebral palsy. Current treatments offer limited neuroprotection, with some showing no long-term benefits for preterm infants.
Area of Science:
- Neonatal neurology
- Perinatal medicine
- Neuroprotection strategies
Background:
- Preterm birth is a leading cause of infant mortality and morbidity, including brain damage and cerebral palsy.
- Brain injury in preterm infants results from factors like perinatal asphyxia, infection, hypoxia, and medical treatments.
- Existing treatment options for preventing or mitigating brain injury in preterm infants are limited.
Purpose of the Study:
- To review current and emerging neuroprotective treatments for preterm infants.
- To evaluate the efficacy of existing interventions like magnesium sulfate and recombinant erythropoietin.
- To identify promising preclinical therapies for reducing brain damage in preterm neonates.
Main Methods:
- Review of clinical trials and preclinical studies on neuroprotective agents.
- Analysis of outcomes from interventions such as magnesium sulfate and recombinant erythropoietin.
- Exploration of novel therapeutic approaches including hypothermia, melatonin, and cell-based therapies.
Main Results:
- Magnesium sulfate showed a small reduction in cerebral palsy risk but no effect on death or disability.
- Recombinant erythropoietin did not improve neurodevelopmental outcomes in extremely preterm infants.
- Promising preclinical findings exist for therapies like therapeutic hypothermia, melatonin, and vitamin D.
Conclusions:
- Current neuroprotective treatments for preterm infants have limited efficacy.
- Further research into novel therapies like therapeutic hypothermia and melatonin is warranted.
- Refinements in clinical care, including optimized corticosteroid use and seizure management, are crucial for improving neurological outcomes.
Abstract:
Preterm birth is associated with a high risk of morbidity and mortality including brain damage and cerebral palsy. The development of brain injury in the preterm infant may be influenced by many factors including perinatal asphyxia, infection/inflammation, chronic hypoxia and exposure to treatments such as mechanical ventilation and corticosteroids. There are currently very limited treatment options available. In clinical trials, magnesium sulfate has been associated with a small, significant reduction in the risk of cerebral palsy and gross motor dysfunction in early childhood but no effect on the combined outcome of death or disability, and longer-term follow up to date has not shown improved neurological outcomes in school-age children. Recombinant erythropoietin has shown neuroprotective potential in preclinical studies but two large randomized trials, in extremely preterm infants, of treatment started within 24 or 48 h of birth showed no effect on the risk of severe neurodevelopmental impairment or death at 2 years of age. Preclinical studies have highlighted a number of promising neuroprotective treatments, such as therapeutic hypothermia, melatonin, human amnion epithelial cells, umbilical cord blood and vitamin D supplementation, which may be useful at reducing brain damage in preterm infants. Moreover, refinements of clinical care of preterm infants have the potential to influence later neurological outcomes, including the administration of antenatal and postnatal corticosteroids and more accurate identification and targeted treatment of seizures.
